Juno Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Juno Therapeutics's estimated annual revenue is currently $39.9M per year.
- Juno Therapeutics's estimated revenue per employee is $193,750
- Juno Therapeutics's total funding is $1.9M.
Employee Data
- Juno Therapeutics has 206 Employees.
- Juno Therapeutics grew their employee count by -4% last year.
Juno Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Executive Medical Director | Reveal Email/Phone |
2 | Director Quality Control | Reveal Email/Phone |
3 | Senior Director, Cell Therapy Counsel | Reveal Email/Phone |
4 | Clinical Trial Manager | Reveal Email/Phone |
5 | Manager, End User Services | Reveal Email/Phone |
6 | Sr. Manager, Warehouse Operations | Reveal Email/Phone |
7 | Manager, Regulatory Affairs | Reveal Email/Phone |
8 | Senior Quality Assurance Project Manager | Reveal Email/Phone |
9 | Apheresis Support Specialist II | Reveal Email/Phone |
10 | Manufacturing Associate III | Reveal Email/Phone |
Juno Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Juno Therapeutics?
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
keywords:Biotechnology, Healthcare, Health and Wellness
$1.9M
Total Funding
206
Number of Employees
$39.9M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Juno Therapeutics News
The meeting launched with a conversation between former Juno Therapeutics executives Hans Bishop and Steve Harr, who both went on to...
The pair once worked together at Seattle flagship cell therapy company Juno Therapeutics, where Bishop was CEO and Harr was COO and CFO.
Though JW independently developed Carteyva, it used the process platform developed by Bristol Myers Squibb subsidiary Juno Therapeutics.
Personal Genome Diagnostics Inc. (PGDx) today announced a $75 million Series B financing co-led by new investor Bristol-Myers Squibb and existing investor New Enterprise Associates (NEA). Other new and existing investors including Inova Strategic Investments, Co-win Healthcare Fund, Helsinn Inve ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 206 | -1% | N/A |
#2 | $73.5M | 207 | 0% | N/A |
#3 | $22.7M | 207 | 42% | $6.4M |
#4 | $61.5M | 207 | 2% | N/A |
#5 | $47.8M | 207 | 24% | N/A |